Analysts Offer Insights on Healthcare Companies: Danaher (DHR), Thermo Fisher (TMO) and Biogen (BIIB)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Danaher (DHR), Thermo Fisher (TMO) and Biogen (BIIB).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Danaher (DHR)
In a report issued on April 23, David Toung from Argus Research maintained a Buy rating on Danaher. The company’s shares closed last Friday at $177.25.
According to TipRanks.com, Toung is a 4-star analyst with an average return of
Currently, the analyst consensus on Danaher is a Strong Buy with an average price target of $237.71, representing a 33.1% upside. In a report issued on April 21, TipRanks – PerPlexity also upgraded the stock to Buy with a $226.00 price target.
See the top stocks recommended by analysts >>
Thermo Fisher (TMO)
In a report released yesterday, Casey Woodring from J.P. Morgan maintained a Buy rating on Thermo Fisher, with a price target of $600.00. The company’s shares closed last Friday at $469.71.
According to TipRanks.com, Woodring is a 1-star analyst with an average return of
Currently, the analyst consensus on Thermo Fisher is a Strong Buy with an average price target of $632.83, implying a 34.9% upside from current levels. In a report issued on April 23, TipRanks – DeepSeek also upgraded the stock to Buy with a $576.00 price target.
Biogen (BIIB)
In a report released yesterday, Chris Schott from J.P. Morgan maintained a Hold rating on Biogen, with a price target of $185.00. The company’s shares closed last Friday at $184.38.
According to TipRanks.com, Schott is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $211.09 average price target, implying a 13.1% upside from current levels. In a report issued on April 10, Morgan Stanley also maintained a Hold rating on the stock with a $200.00 price target.
Read More on DHR:
